The Accreditation Council for CME is not the only organization suggesting that regulations regarding CME presenters' financial ties to pharmaceutical companies should be strengthened. The American Society of Clinical Oncology has changed its rules regarding conflict of interest and clinical trials — and the new policy, adopted in April, is far stricter and can affect speakers at ASCO meetings.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments
